Companies such as Moderna Therapeutics, Curevac AG and Argos Therapeutics are studying a range of candidates in infectious diseases, some with encouraging first-in-human data.
‘Nucleic acid-based therapeutics’ based on mRNA, are a group of technologies with potential applications in vaccination for cancer, infectious diseases and diseases requiring protein replacement therapy. Improvements in mRNA formulation and delivery using lipid nanoparticle and cationic nanoparticle encapsulation have overcome early issues with stability and complex dendritic cell (DC) loading techniques. Landmark studies have shown that directly injected encapsulated mRNA is both safe and immunogenic triggering humoral and cellular immune responses in healthy and cancer patients.
mRNA vaccines are potentially disruptive because they provide some critical advantages over existing vaccine antigen approaches.
This MarketVIEW product consists of a detailed Executive presentation (~135 .pdf slides) and MS-Excel workbook (.xls) which gives a comprehensive overview of mRNA technologies and their potential application in the prophylatic and therapeutic setting for cancer and infectious diseases indications. An R&D pipeline analysis is provided which details all current mRNA candidates at clinical stages.
Major companies and alliances are outlined with a focus on each individual program (infectious diseases). Importantly, drawing upon VacZine Analytics' research portfolio, a strategic analysis is included whereby opportunities associated with mRNA technologies are contrasted with the competitive threat level should a new vaccine progress to licensure. This report is ideal for any client who wishes to understand the potential significance of this emerging field.
For more information, please contact info@vaczine-analytics.com or www.vaczine-analytics.com
VacZine Analytics, a world-leading supplier of vaccine-related commercial analyses is a trading division of Assay Advantage Ltd (UK Company No: 5807728, UK VAT: 883584084)